Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary
heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet.1994;344:1383-1389.
Sacks FM, Pfeffer MA, Moye LA.
et al. The effect of pravastatin on coronary events after myocardial infarction
in patients with average cholesterol levels. N Engl J Med.1996;335:1001-1009.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID)
Study Group. Prevention of cardiovascular events and death with pravastatin in patients
with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med.1998;339:1349-1357.
Downs JR, Clearfield M, Weis S.
et al. Primary prevention of acute coronary events with lovastatin in men
and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA.1998;279:1615-1622.
Shepherd J, Cobbe SM, Ford I.
et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia:
West of Scotland Coronary Prevention Study Group. N Engl J Med.1995;333:1301-1307.
Schwartz GG, Olsson AG, Ezekowitz MD.
et al. Effects of atorvastatin on early recurrent ischemic events in acute
coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA.2001;285:1711-1718.
Heeschen C, Hamm CW, Laufs U.
et al. on behalf of the Platelet Receptor Inhibition in Ischemic Syndrome
Management (PRISM) investigators. Withdrawal of statins increases event rates in patients with acute
coronary syndromes. Circulation.2002;105:1446-1452.
Andrade SE, Walker AM, Gottlieb LK.
et al. Discontinuation of antihyperlipidemic drugs—do rates reported
in clinical trials reflect rates in primary care settings? N Engl J Med.1995;332:1125-1131.
Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering
drugs. Med J Aust.1996;164:208-211.
Avorn J, Monette J, Lacour A.
et al. Persistence of use of lipid-lowering medications: a cross-national
Eriksson M, Hadell K, Holme I.
et al. Adherence with and efficacy of treatment with pravastatin and cholestyramine:
a randomized study on lipid-lowering in primary care. J Intern Med.1998;243:373-380.
Cholesterol Testing and Treatment in Adults: The Final Report . Saskatoon, Saskatchewan: Health Services Utilization and Research
McDermott MM, Schmitt B, Wallner E. Impact of medication nonadherence on coronary heart disease outcomes:
a critical review. Arch Intern Med.1997;157:1921-1929.
Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med.1984;100:258-268.
Jackevicius CA, Anderson GM, Leiter L, Tu JV. Use of the statins in patients after acute myocardial infarction: does
evidence change practice? Arch Intern Med.2001;161:183-188.
Rochon PA, Tu JV, Anderson GM.
et al. Rate of heart failure and 1-year survival for older people receiving
low-dose beta-blocker therapy after myocardial infarction. Lancet.2000;356:639-644.
Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods,
validity, and applications. J Clin Epidemiol.1997;50:105-116.
Insull W. The problem of adherence to cholesterol altering therapy. J Intern Med.1997;241:317-325.
Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: implications
for primary care. Am J Manag Care.1999;5:437-444.
Bybee KA, Wright RS, Williams BA.
et al. Effect of concomitant or very early statin administration on in-hospital
mortality and reinfarction in patients with acute myocardial infarction. Am J Cardiol.2001;87:771-774, A7.
Aronow HD, Topol EJ, Roe MT.
et al. Effect of lipid-lowering therapy on early mortality after acute coronary
syndromes: an observational study. Lancet.2001;357:1063-1068.
Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year
Fodor JG, Frolich JJ, Genest Jr JJ, McPherson R. Recommendations for the management and treatment of dyslipidemia. Can Med Assoc J.2000;162:1441-1447.
Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults. Summary of the second report of the National Cholesterol Education
Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA.1993;269:3015-3023.
The West of Scotland Coronary Prevention Study Group. Compliance and adverse event withdrawal: their impact on the West of
Scotland Coronary Prevention Study. Eur Heart J.1997;18:1718-1724.
Rudd P. Compliance with antihypertensive therapy: a shifting paradigm. Cardiol Rev.1994;2:230-240.
Jones P, Kafonek S, Laurona I, Hunninghake D.for the CURVES Investigators. Comparative dose efficacy of atorvastatin versus simvastatin, pravastatin,
lovastatin, and fluvastatin in patients with hypercholesterolemia. Am J Cardiol.1998;81:582-587.
Muhlestein JB, Horne BD, Bair TL.
et al. Usefulness of in-hospital prescription of statin agents after angiographic
diagnosis of coronary artery disease in improving continued compliance and
reduced mortality. Am J Cardiol.2001;87:257-261.
Feely J, Chan R, McManus J, O'Shea B. The influence of hospital-based prescribers on prescribing in general
Kravitz RL, Hays RD, Sherbourne CD.
et al. Recall of recommendations and adherence to advice among patients with
chronic medical conditions. Arch Intern Med.1993;153:1869-1878.
Helping patients follow the treatments you prescribe. In: Sackett DL, Haynes RB, Guyatt GH, Tugwell P, eds. Clinical
Epidemiology: A Basic Science for Clinical Medicine . Toronto, Ontario: Little
Brown & Co Inc; 1991.